123 related articles for article (PubMed ID: 37926860)
1. Development and validation of a model to predict acute kidney injury following high-dose methotrexate in patients with lymphoma.
Rice ML; Barreto EF; Rule AD; Martin CE; Truong HL; Mara KC; Kashani KB; Thompson CA; Witzig TE; Barreto JN
Pharmacotherapy; 2024 Jan; 44(1):4-12. PubMed ID: 37926860
[TBL] [Abstract][Full Text] [Related]
2. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.
Barreto JN; Peterson KT; Barreto EF; Mara KC; Dierkhising RA; Leung N; Witzig TE; Thompson CA
Support Care Cancer; 2021 Sep; 29(9):5293-5301. PubMed ID: 33661366
[TBL] [Abstract][Full Text] [Related]
3. Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients.
Wang Y; Wei L; Guan Y; Wang Q; Xie Q; Hao C
Ren Fail; 2020 Nov; 42(1):1111-1117. PubMed ID: 33164656
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.
Amitai I; Rozovski U; El-Saleh R; Shimony S; Shepshelovich D; Rozen-Zvi B; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2020 Oct; 38(4):584-588. PubMed ID: 32506594
[TBL] [Abstract][Full Text] [Related]
5. Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma.
DeFino CE; Barreto JN; Pawlenty AG; Ruff MW; Carabenciov ID; Mara KC; Thompson CA
Pharmacotherapy; 2021 May; 41(5):430-439. PubMed ID: 33655525
[TBL] [Abstract][Full Text] [Related]
6. Outpatient administration of high-dose methotrexate in adults without drug monitoring - a case-control study of risk factors for acute kidney injury.
Alves C; Pereira J; Rego EM; Rocha V; Silva WF
Hematol Transfus Cell Ther; 2023 Dec; ():. PubMed ID: 38233304
[TBL] [Abstract][Full Text] [Related]
7. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for predicting high dose methotrexate associated acute kidney injury in children with acute lymphoblastic leukemia.
Li H; Xu Q; Wang Y; Chen K; Li J
Cancer Chemother Pharmacol; 2020 Jan; 85(1):95-103. PubMed ID: 31676986
[TBL] [Abstract][Full Text] [Related]
8. Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing.
Ibarra M; Combs R; Taylor ZL; Ramsey LB; Mikkelsen T; Buddington RK; Heldrup J; Barreto JN; Guscott M; Lowe J; Hurmiz C; Marada S; Howard SC; Schaiquevich P
Br J Clin Pharmacol; 2023 Feb; 89(2):660-671. PubMed ID: 35998099
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for acute kidney injury after high-dose methotrexate therapy: a single-center study and narrative review.
Liang CA; Su YC; Lin SJ; Tsai TH
Eur J Clin Pharmacol; 2023 Jun; 79(6):789-800. PubMed ID: 37060460
[TBL] [Abstract][Full Text] [Related]
10. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.
Gros L; Roldán A; Cabero-Martínez A; Domínguez-Pinilla N; de la Fuente A; González-Barca E; Tasso M; Torrent M; Gallardo E; Del Cerro I; Giró-Perafita A; Badia X
J Oncol Pharm Pract; 2023 Jun; 29(4):794-801. PubMed ID: 35147457
[TBL] [Abstract][Full Text] [Related]
11. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.
Ramsey LB; Balis FM; O'Brien MM; Schmiegelow K; Pauley JL; Bleyer A; Widemann BC; Askenazi D; Bergeron S; Shirali A; Schwartz S; Vinks AA; Heldrup J
Oncologist; 2018 Jan; 23(1):52-61. PubMed ID: 29079637
[TBL] [Abstract][Full Text] [Related]
12. The Application of
Wang L; Chen K; Xu Q
Biomed Res Int; 2020; 2020():3687134. PubMed ID: 33299868
[TBL] [Abstract][Full Text] [Related]
13. Preventing and Managing Toxicities of High-Dose Methotrexate.
Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
[TBL] [Abstract][Full Text] [Related]
14. Derivation and External Validation of a Risk Index for Predicting Acute Kidney Injury Requiring Kidney Replacement Therapy After Noncardiac Surgery.
Wilson TA; de Koning L; Quinn RR; Zarnke KB; McArthur E; Iskander C; Roshanov PS; Garg AX; Hemmelgarn BR; Pannu N; James MT
JAMA Netw Open; 2021 Aug; 4(8):e2121901. PubMed ID: 34424303
[TBL] [Abstract][Full Text] [Related]
15. High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course.
O'Donoghue DF; Truong HL; Finnes HD; McDonald JS; May HP; Ansell SM; Bennani NN; Habermann TM; Inwards DJ; Johnston PB; Khurana A; Lin Y; Micallef IN; Nowakowski GS; Paludo J; Porrata LF; Thanarajasingam G; Thompson CA; Villasboas JC; Wang Y; Witzig TE; Leung N
JCO Oncol Pract; 2022 Dec; 18(12):e1908-e1917. PubMed ID: 36240468
[TBL] [Abstract][Full Text] [Related]
16. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
17. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
[TBL] [Abstract][Full Text] [Related]
18. Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study.
Gupta S; Glezerman IG; Hirsch JS; Chen KL; Devaraj N; Wells SL; Seitter RH; Kaunfer SA; Jose AM; Rao SP; Ortega JL; Green-Lingren O; Hayden R; Bendapudi PK; Chute DF; Sise ME; Jhaveri KD; Page VD; Abramson MH; Motwani SS; Xu W; Sehgal K; Reynolds KL; Bansal A; Abudayyeh A; Leaf DE
BMJ; 2024 Mar; 384():e077169. PubMed ID: 38538012
[TBL] [Abstract][Full Text] [Related]
19. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
[TBL] [Abstract][Full Text] [Related]
20. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.
Christensen AM; Pauley JL; Molinelli AR; Panetta JC; Ward DA; Stewart CF; Hoffman JM; Howard SC; Pui CH; Pappo AS; Relling MV; Crews KR
Cancer; 2012 Sep; 118(17):4321-30. PubMed ID: 22252903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
